The board chairman of Chinese pharmaceutical company Hunan Fangsheng Pharmaceutical Co., Ltd has been fined 600,000 yuan. (~€77,000/~$91,000) in an insider trading case. Chinese officials started investigating the company in June 2019 following a rise in Fangshen shares the previous April when the company announced it had signed a cooperation agreement with the government of Huize County, Yunnan, to develop hemp farming and processing operations. The company later admitted in a subsequent announcement that the project was still in the planning phase and faced uncertainty, causing Fangshen’s stock to fall sharply.
Posted By: HempToday® January 26, 2021
Like HempToday? How you can support us
Your donations help us to keep HempToday open for all readers, regardless of what they can afford to pay. Through this “information equality” we're able to support hemp entrepreneurs and stakeholders all over the world by keeping a spotlight on hemp and all the promise it offers for economic development and healing our planet.